Publications by authors named "Maria Teresa Inaraja-Bobo"
Article Synopsis
- The study analyzed potential drug-drug interactions (pDDIs) in COVID-19 patients, focusing on those treated with specific medications during the first wave of the pandemic.
- Out of 350 patients, 62.3% had at least one pDDI, with significant impacts noted on the QTc interval in a small fraction of patients, indicating potential risks.
- While the incidence of pDDIs was high, clinically significant adverse effects were relatively low, highlighting the need for careful monitoring of drug interactions in COVID-19 treatment.
Case: A 44-year-old man was diagnosed with ankylosing spondylitis, on treatment with infliximab. After three doses, he was admitted to hospital with fever, fatigue and nausea. A bone marrow biopsy confirmed haemophagocytic syndrome.
View Article and Find Full Text PDFObjective: To evaluate the impact of implementing new programs to improve the quality of the pharmaceutical care and unit-dose distribution system for in-patients.
Material And Methods: An observational and prospective study was carried out in a general hospital during two different six-monthly period. Transcription and dispensation errors were evaluated in twelve wards during the first six months.